Search research articles
Contact Us
Filters
Showing results (91-100 of 112) with videos related to
Page
of 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 6, 2021
Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Chunmeng Wang, Yang Liu, Liang Dong, et al.
Journal of Alzheimer'S Disease & Parkinsonism
|
May 14, 2019
Identification and Analysis of Alzheimer's Candidate Genes by an Amplitude Deviation Algorithm
Chaoyang Pang, Hualan Yang, Benqiong Hu, et al.
Frontiers in Cardiovascular Medicine
|
February 4, 2026
Coronary complexity and inflammatory burden in HIV-infected patients with acute coronary syndrome: a two-year prospective cohort study in China
Qiang Wu, Liqin Sun, Chunxiao Lu, et al.
Nature Communications
|
August 13, 2024
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial
Liang Dong, Zhi Cao, Meixia Chen, et al.
International Journal of Cancer
|
April 18, 2018
Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer
Meixia Chen, Jing Nie, Yang Liu, et al.
Journal of Hematology & Oncology
|
April 5, 2020
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai, Zhiqiang Wu, Hejin Jia, et al.
Journal of Hematology & Oncology
|
May 20, 2020
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai, Zhiqiang Wu, Hejin Jia, et al.
Clinical and Translational Science
|
July 2, 2025
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial
Yuyang Dai, Feng Wu, Siyang Ni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2020
Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Qian Mei, Wenying Zhang, Yang Liu, et al.
Bioscience Trends
|
August 23, 2023
Geriatric syndromes, chronic inflammation, and advances in the management of frailty: A review with new insights
Niuniu Li, Gaolin Liu, Hong Gao, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 112) with videos related to
Sort By:
Page
of 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 6, 2021
Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Chunmeng Wang, Yang Liu, Liang Dong, et al.
Journal of Alzheimer'S Disease & Parkinsonism
|
May 14, 2019
Identification and Analysis of Alzheimer's Candidate Genes by an Amplitude Deviation Algorithm
Chaoyang Pang, Hualan Yang, Benqiong Hu, et al.
Frontiers in Cardiovascular Medicine
|
February 4, 2026
Coronary complexity and inflammatory burden in HIV-infected patients with acute coronary syndrome: a two-year prospective cohort study in China
Qiang Wu, Liqin Sun, Chunxiao Lu, et al.
Nature Communications
|
August 13, 2024
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial
Liang Dong, Zhi Cao, Meixia Chen, et al.
International Journal of Cancer
|
April 18, 2018
Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer
Meixia Chen, Jing Nie, Yang Liu, et al.
Journal of Hematology & Oncology
|
April 5, 2020
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai, Zhiqiang Wu, Hejin Jia, et al.
Journal of Hematology & Oncology
|
May 20, 2020
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai, Zhiqiang Wu, Hejin Jia, et al.
Clinical and Translational Science
|
July 2, 2025
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial
Yuyang Dai, Feng Wu, Siyang Ni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2020
Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Qian Mei, Wenying Zhang, Yang Liu, et al.
Bioscience Trends
|
August 23, 2023
Geriatric syndromes, chronic inflammation, and advances in the management of frailty: A review with new insights
Niuniu Li, Gaolin Liu, Hong Gao, et al.
Page
of 12